CD4 + CD126 low/- Foxp3 + Cell Population Represents a Superior Subset of Regulatory T Cells in Treating Autoimmune Diseases

• Published in: Molecular therapy 2020-11, Vol.28 (11), p.2406
• Main Authors: Chen, Ye, Xu, Zhenjian, Liang, Rongzhen, Wang, Julie, Xu, Anping, Na, Ning, Li, Bin, Wang, Ruoning, Joseph, Miller, Olsen, Nancy, Hsueh, Willa, Zheng, Song Guo
• Format: Article
• Language: English
• Subjects: Autoimmune Diseases - immunology; Autoimmune Diseases - metabolism; Autoimmune Diseases - therapy; Autoimmunity; Biomarkers; Forkhead Transcription Factors - metabolism; Gene Expression; Humans; Immunophenotyping; Immunotherapy - methods; Interleukin-6 - metabolism; Receptors, Interleukin-6 - metabolism; T-Lymphocyte Subsets - immunology; T-Lymphocyte Subsets - metabolism; T-Lymphocytes, Regulatory - immunology; T-Lymphocytes, Regulatory - metabolism
• ISSN: 1525-0024
• DOI: 10.1016/j.ymthe.2020.07.020

CD4 Foxp3 regulatory T (Treg) cells are crucial for maintaining homeostasis and preventing autoimmune diseases. Nonetheless, we and others have previously reported that natural Treg cells are unstable and dysfunctional in the inflamed environment with a high-salt diet, limiting the Treg function in disease control. In this study, we made an innovative observation showing a high degree of heterogeneity within the Treg pool. We identified that CD126, interleukin (IL)-6 receptor alpha chain, contributed to Treg cell instability. Using a series of in vitro and in vivo experimental approaches, we demonstrated that CD126 Treg cells presented greater function and were more stable than CD126 nTreg cells, even in the presence of IL-6 and inflammation. Blockade of programmed death-1 (PD-1) interrupted CD126 nTreg cell stability. Additionally, CD126 Treg cells can treat colitis and established collagen-induced arthritis, while the CD126 cell population failed to do this. Moreover, we noted that CD126 expression of Treg cells had a positive correlation to rheumatoid arthritis (RA) severity and the stability of Treg cells. Our results strongly suggest that the manipulation of CD126 nTreg cells could be a novel strategy for the treatment of autoimmune diseases and for other conditions associated with a deficit of Treg cells.